Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404

Indian Indapamide Market

Indian Indapamide Market Size, Share & Trends Analysis By Product Type (Immediate-Release Tablets, Sustained/Extended-Release Tablets), By Strength (1.25 mg, 2.5 mg, Other Customized Dosages), By Application (Hypertension, Edema, Heart Failure), Forecast Period (2026-2035)

Published: Oct 2026 | Report Code: OMR2022239 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

India indapamide market was valued at $11.2 million in 2025 and is projected to reach $15.0 million by 2035, growing at a CAGR of 3.0% from 2026 to 2035. The India indapamide market is supported primarily by the continuing need for pharmacological management of hypertension and the use of diuretic-based therapies within cardiovascular treatment. Indapamide is available in India as both a standalone antihypertensive and as part of fixed-dose combinations with other blood-pressure-lowering agents. Sustained-release formulations remain an important product format because they provide an established option for longer-duration blood-pressure management. The market also includes a broad generic and branded-generic supplier base, increasing product availability across prescription channels. Recent Indian clinical evidence has further examined indapamide in combination regimens for hypertension management.

Market Dynamics

Sustained-Release Formulations

Sustained-release indapamide remains an important trend within the Indian market because commercially available products include established prolonged-release formulations. Servier India markets Natrilix SR 1.5 mg, while several Indian manufacturers and marketers offer alternative sustained-release products. The formulation is particularly relevant to chronic hypertension treatment because it is designed for prolonged drug release rather than immediate release. Recent Indian product listings also show continued availability of indapamide sustained-release tablets from multiple suppliers. This indicates continued manufacturer participation in the sustained-release segment alongside established branded products.

Combination Antihypertensive Therapy

Combination therapy is an important market trend because indapamide is increasingly represented in fixed-dose products alongside other antihypertensive agents. Products marketed in India include combinations with amlodipine, perindopril and telmisartan, allowing indapamide to be incorporated into multi-drug treatment approaches. Zydus, Servier, Lupin, Glenmark and Eris are among companies with documented indapamide-containing combination products. Indian clinical research published in 2025 also evaluated amlodipine–indapamide and perindopril–indapamide combinations in patients with hypertension.

Market Segmentation

  • Based on the product type, the market is segmented into immediate-release (IR) tablets and sustained/extended-release (SR/ER) tablets.
  • Based on the strength, the market is segmented into 1.25 mg, 2.5 mg, and other customized dosages.
  • Based on the application, the market is segmented into hypertension, edema, and heart failure.

Sustained-Release Tablets Segment to Lead the Market with the Largest Share

Sustained-release tablets represent an important subsegment of the India indapamide market because several established products use this formulation. Natrilix SR, Diurix SR, Indap SR, and other products demonstrate continued availability of sustained-release indapamide through the Indian pharmaceutical supply chain.

Hypertension: A Key Segment in Market Growth

Hypertension represents the principal therapeutic application for indapamide in India. The drug is marketed both as a standalone treatment and in combination with other antihypertensive agents, while Indian clinical research continues to evaluate indapamide-based treatment strategies for blood-pressure control.

Market Players Outlook

The major companies operating in the India indapamide market include Servier India Private Limited, Torrent Pharmaceuticals Limited, Zydus Healthcare Limited, Eris Lifesciences Limited, and Lupin Limited, among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

  • Taj Pharmaceuticals added Indapamide Sustained Release Tablets 1.5 mg to its India portfolio. The company describes the product as a film-coated sustained-release tablet containing indapamide and identifies it for antihypertensive use, with documentation including product information, GMP-related documents, and stability-study materials. The same portfolio also lists Indapamide Tablets 2.5 mg.

The Report Covers

  • Market value data analysis for 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Key companies operating in the India indapamide market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • India Indapamide Market Sales Analysis – Product Type | Strength | Application ($ Million)
  • Indapamide Market Sales Performance of Top Countries
    • Research Methodology
  • Primary Research Approach
  • Secondary Research Approach
    • Market Snapshot
  1. Market Overview and Insights
    • Scope of the Study
    • Analyst Insight & Current Market Trends
      • Key Indapamide Industry Trends
      • Market Recommendations
    • Porter's Five Forces Analysis for the Indapamide Market
      • Competitive Rivalry
      • Threat of New Entrants
      • Bargaining Power of Suppliers
      • Bargaining Power of Buyers
      • Threat of Substitutes
  1. Market Determinants
    • Market Drivers
      • Drivers For India Indapamide Market: Impact Analysis
    • Market Pain Points and Challenges
      • Restraints For India Indapamide Market: Impact Analysis
    • Market Opportunities
      • Opportunities For India Indapamide Market: Impact Analysis
  1. Competitive Landscape
    • Competitive Dashboard – Indapamide Market Revenue and Share by Manufacturers
  • Indapamide Product Comparison Analysis
  • Top Market Player Ranking Matrix
    • Key Company Analysis
      • Eris Lifesciences Limited
        • Overview
        • Product Portfolio
        • Financial Analysis
        • SWOT Analysis
        • Business Strategy
      • Lupin Limited
        • Overview
        • Product Portfolio
        • Financial Analysis
        • SWOT Analysis
        • Business Strategy
      • Servier India Private Limited
        • Overview
        • Product Portfolio
        • Financial Analysis
        • SWOT Analysis
        • Business Strategy
      • Torrent Pharmaceuticals Limited
        • Overview
        • Product Portfolio
        • Financial Analysis
        • SWOT Analysis
        • Business Strategy
      • Zydus Healthcare Limited
        • Overview
        • Product Portfolio
        • Financial Analysis
        • SWOT Analysis
        • Business Strategy
      • Top Winning Strategies by Market Players
        • Merger and Acquisition
        • Product Launch
        • Partnership And Collaboration
  1. India Indapamide Market Sales Analysis by Product Type ($ Million)
    • Immediate-Release (IR) Tablets
    • Sustained/Extended-Release (SR/ER) Tablets
  1. India Indapamide Market Sales Analysis by Strength ($ Million)
    • 25 mg
    • 5 mg
    • Other Customized Dosages
  1. India Indapamide Market Sales Analysis by Application ($ Million)
    • Hypertension
    • Edema (Fluid Retention)
    • Heart Failure (Adjunct Therapy)
  1. Company Profiles
    • ADN Life Sciences
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Bal Pharma Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Care Formulation Labs Private Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Colgen Pharma
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Dexter Laboratories
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Druto Laboratories
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • East West Pharma
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Elder Pharmaceuticals Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Emcure Pharmaceuticals Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Eris Lifesciences Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Glenmark Pharmaceuticals Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Grefith Life Sciences Private Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Ipca Laboratories Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Lupin Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Mandar Pharmaceuticals Private Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Micro Labs Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Modi-Mundi Pharma Private Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Orchid Chemicals & Pharmaceuticals Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Prevego Healthcare & Research Private Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Servier India Private Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Steris Healthcare Private Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Taj Pharmaceuticals Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Torrent Pharmaceuticals Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Trumac Healthcare
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies
    • Zydus Healthcare Limited
      • Quick Facts
      • Company Overview
      • Product Portfolio
      • Business Strategies

1. India Indapamide Market Research and Analysis by Product Type, 2025–2035 ($ Million)

2. India Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)

3. India Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)

4. India Indapamide Market Research and Analysis by Strength, 2025–2035 ($ Million)

5. India 1.25 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)

6. India 2.5 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)

7. India Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)

8. India Indapamide Market Research and Analysis by Application, 2025–2035 ($ Million)

9. India Indapamide for Hypertension Research and Analysis by Region, 2025–2035 ($ Million)

10. India Indapamide for Edema (Fluid Retention) Research and Analysis by Region, 2025–2035 ($ Million)

11. India Indapamide for Heart Failure (Adjunct Therapy) Research and Analysis by Region, 2025–2035 ($ Million)

1. India Indapamide Market Share by Product Type, 2025 vs 2035 (%)

2. India Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)

3. India Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)

4. India Indapamide Market Share by Strength, 2025 vs 2035 (%)

5. India 1.25 mg Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)

6. India 2.5 mg Indapamide Market Research and Analysis by Region, 2025 vs 2035 (%)

7. India Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)

8. India Indapamide Market Share by Application, 2025 vs 2035 (%)

9. India Indapamide for Hypertension Market Research and Analysis by Region, 2025 vs 2035 (%)

10. India Indapamide for Edema (Fluid Retention) Market Research and Analysis by Region, 2025 Vs 2035 (%)

11. India Indapamide for Heart Failure (Adjunct Therapy) Market Research and Analysis by Region, 2025 Vs 2035 (%)